688180 君實生物
按盤價 
43.970 +0.590 (+1.360%) | 2025/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 1,168,384 | 48.64% | 1,948,317 | 1,502,550 | 1,453,493 | 4,024,841 | |
| 減：營業總成本 | 1,659,108 | 15.64% | 3,215,859 | 3,811,860 | 4,102,931 | 4,728,260 | |
| 其中:營業成本 | 232,973 | 10.72% | 410,682 | 540,976 | 504,308 | 1,244,540 | |
| 財務費用 | 25,547 | -2,845.18% | (144) | (67,086) | (80,955) | 31,366 | |
| 資產減值損失 | (50,739) | 13,196.10% | (88,179) | (126,314) | (21,974) | (13,647) | |
| 公允價值變動收益 | 55,514 | -272.68% | (47,679) | (149,177) | (9,277) | 112,933 | |
| 投資收益 | (20,282) | -27.14% | (23,554) | 73,990 | (41,932) | (47,187) | |
| 其中：對聯營企業和合營企業的投資收益 | (25,209) | -10.68% | (35,026) | (60,485) | (71,031) | (48,463) | |
| 營業利潤 | (475,011) | -29.70% | (1,338,825) | (2,457,442) | (2,665,914) | (558,275) | |
| 利潤總額 | (485,212) | -29.08% | (1,357,557) | (2,491,695) | (2,677,184) | (595,000) | |
| 減：所得稅費用 | (19,538) | -650.19% | 22,552 | 43,995 | (93,107) | 135,533 | |
| 淨利潤 | (465,673) | -32.29% | (1,380,109) | (2,535,689) | (2,584,077) | (730,534) | |
| 減：非控股權益 | (52,978) | 23.91% | (99,182) | (252,257) | (196,028) | (9,624) | |
| 股東淨利潤 | (412,696) | -36.01% | (1,280,926) | (2,283,432) | (2,388,050) | (720,910) | |
市場價值指標 | |||||||
| 每股收益 (元) * | -0.420 | -35.38% | -1.300 | -2.320 | -2.600 | -0.810 | |
| 每股派息 (元) * | -- | -- | -- | -- | -- | -- | |
| 每股淨資產 (元) * | 6.207 | -5.56% | 5.946 | 7.260 | 9.650 | 8.720 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 28/08/2025 16:25 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
